Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options by Lewis R, Bewersdorf JP, Zeidan AM

Get full text

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia by Uy N, Nadeau M, Stahl M, Zeidan AM

Get full text

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis by Bewersdorf JP, Jaszczur SM, Afifi S, Zhao JC, Zeidan AM

Get full text

Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review by Cortes, JE, Candoni, A, Clark, RE, Leber, B, Montesinos, P, Vyas, P, Zeidan, AM, Heuser, M

Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the ra... by DiNardo, CD, Montesinos, P, Schuh, AC, Papayannidis, C, Vyas, P, Wei, AH, Zeidan, AM, Bluemmert, I, Yu, X, Hasan, M, Martin-Regueira, P, de Botton, S

Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (A... by DiNardo, CD, Dohner, H, Zeidan, AM, Schuh, AC, Vyas, P, Stein, EM, Wei, AH, de Botton, S, Chen, C, Lord-Bessen, J, Martin-Regueira, P, Lersch, F, Gong, J, Guo, S, Shi, L, Montesinos, P

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, p... by DiNardo, CD, Schuh, AC, Stein, EM, Montesinos, P, Wei, AH, de Botton, S, Zeidan, AM, Fathi, AT, Kantarjian, HM, Bennett, JM, Frattini, MG, Martin-Regueira, P, Lersch, F, Gong, J, Hasan, M, Vyas, P, Döhner, H

Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemi... by Dinardo, CD, Montesinos, P, Schuh, AC, Papayannidis, C, Vyas, P, Wei, AH, Zeidan, AM, Chen, C, Lord-Bessen, J, Yu, P, Shi, L, Guo, S, Bluemmert, I, Yu, X, Hasan, M, Martin Regueira, P, De Botton, S

A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes by Sekeres, MA, Schuster, M, Joris, M, Krauter, J, Maertens, J, Breems, D, Gyan, E, Kovacsovics, T, Verma, A, Vyas, P, Wang, ES, Ching, K, O'Brien, T, Gallo Stampino, C, Ma, WW, Kudla, A, Chan, G, Zeidan, AM

Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia by DiNardo, CD, Stein, AS, Stein, EM, Fathi, AT, Frankfurt, O, Schuh, AC, Döhner, H, Martinelli, G, Patel, PA, Raffoux, E, Tan, P, Zeidan, AM, de Botton, S, Kantarjian, HM, Stone, RM, Frattini, MG, Lersch, F, Gong, J, Gianolio, DA, Zhang, V, Franovic, A, Fan, B, Goldwasser, M, Daigle, S, Choe, S, Wu, B, Winkler, T, Vyas, P

Luspatercept in patients with lower-risk myelodysplastic syndromes by Fenaux, P, Platzbecker, U, Mufti, GJ, Garcia-Manero, G, Buckstein, R, Santini, V, Díez-Campelo, M, Finelli, C, Cazzola, M, Ilhan, O, Sekeres, MA, Falantes, JF, Arrizabalaga, B, Salvi, F, Giai, V, Vyas, P, Bowen, D, Selleslag, D, DeZern, AE, Jurcic, JG, Germing, U, Götze, KS, Quesnel, B, Beyne-Rauzy, O, Cluzeau, T, Voso, M-T, Mazure, D, Vellenga, E, Greenberg, PL, Hellström-Lindberg, E, Zeidan, AM, Adès, L, Verma, A, Savona, MR, Laadem, A, Benzohra, A, Zhang, J, Rampersad, A, Dunshee, DR, Linde, PG, Sherman, ML, Komrokji, RS, List, AF

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MD... by Stahl, M, Bewersdorf, JP, Xie, Z, Porta, MGD, Komrokji, R, Xu, ML, Abdel-Wahab, O, Taylor, J, Steensma, DP, Starczynowski, DT, Sekeres, MA, Sanz, G, Sallman, DA, Roboz, GJ, Platzbecker, U, Patnaik, MM, Padron, E, Odenike, O, Nimer, SD, Nazha, A, Majeti, R, Loghavi, S, Little, RF, List, AF, Kim, TK, Hourigan, CS, Hasserjian, RP, Halene, S, Griffiths, EA, Gore, SD, Greenberg, P, Figueroa, ME, Fenaux, P, Efficace, F, DeZern, AE, Daver, NG, Churpek, JE, Carraway, HE, Buckstein, R, Brunner, AM, Boultwood, J, Borate, U, Bejar, R, Bennett, JM, Wei, AH, Santini, V, Savona, MR, Zeidan, AM

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts by Zeidan, AM, Boddu, PC, Patnaik, MM, Bewersdorf, JP, Stahl, M, Rampal, RK, Shallis, R, Steensma, DP, Savona, MR, Sekeres, MA, Roboz, GJ, DeAngelo, DJ, Schuh, AC, Padron, E, Zeidner, JF, Walter, RB, Onida, F, Fathi, A, DeZern, A, Hobbs, G, Stein, EM, Vyas, P, Wei, AH, Bowen, DT, Montesinos, P, Griffiths, EA, Verma, AK, Keyzner, A, Bar-Natan, M, Navada, SC, Kremyanskaya, M, Goldberg, AD, Al-Kali, A, Heaney, ML, Nazha, A, Salman, H, Luger, S, Pratz, KW, Konig, H, Komrokji, R, Deininger, M, Cirici, BX, Bhatt, VR, Silverman, LR, Erba, HP, Fenaux, P, Platzbecker, U, Santini, V, Wang, ES, Tallman, MS